Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed at $43.28 up 0.89% from its previous closing price of $42.9. In other words, the price has increased by $0.89 from its previous closing price. On the day, 0.93 million shares were traded. CRNX stock price reached its highest trading level at $44.6954 during the session, while it also had its lowest trading level at $42.35.
Ratios:
For a deeper understanding of Crinetics Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.80 and its Current Ratio is at 17.80. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on July 10, 2025, initiated with a Neutral rating and assigned the stock a target price of $36.
On March 25, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $60.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 01 ’25 when Pizzuti Dana sold 5,000 shares for $41.81 per share. The transaction valued at 209,050 led to the insider holds 66,270 shares of the business.
DANA PIZZUTI bought 5,000 shares of CRNX for $208,250 on Oct 01 ’25. On Sep 26 ’25, another insider, Struthers Richard Scott, who serves as the President & CEO of the company, sold 4,000 shares for $45.00 each. As a result, the insider received 180,000 and left with 106,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 4075936768 and an Enterprise Value of 2929512960. For the stock, the TTM Price-to-Sale (P/S) ratio is 2932.33 while its Price-to-Book (P/B) ratio in mrq is 3.48. Its current Enterprise Value per Revenue stands at 2104.535 whereas that against EBITDA is -6.981.
Stock Price History:
The Beta on a monthly basis for CRNX is 0.25, which has changed by -0.23654968 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, CRNX has reached a high of $62.53, while it has fallen to a 52-week low of $24.10. The 50-Day Moving Average of the stock is 13.42%, while the 200-Day Moving Average is calculated to be 27.81%.
Shares Statistics:
For the past three months, CRNX has traded an average of 1.47M shares per day and 1211150 over the past ten days. A total of 94.13M shares are outstanding, with a floating share count of 87.11M. Insiders hold about 7.50% of the company’s shares, while institutions hold 107.85% stake in the company. Shares short for CRNX as of 1760486400 were 12440159 with a Short Ratio of 8.49, compared to 1757894400 on 14750119. Therefore, it implies a Short% of Shares Outstanding of 12440159 and a Short% of Float of 15.03.
Earnings Estimates
Its stock is currently analyzed by 13.0 different market analysts. The consensus estimate for the next quarter is -$1.28, with high estimates of -$1.06 and low estimates of -$1.65.
Analysts are recommending an EPS of between -$3.99 and -$5.36 for the fiscal current year, implying an average EPS of -$4.78. EPS for the following year is -$4.98, with 13.0 analysts recommending between -$3.9 and -$7.06.
Revenue Estimates
For the next quarter, 12 analysts are estimating revenue of $3.17M. There is a high estimate of $5.7M for the next quarter, whereas the lowest estimate is $1M.
A total of 14 analysts have provided revenue estimates for CRNX’s current fiscal year. The highest revenue estimate was $7.31M, while the lowest revenue estimate was $3.4M, resulting in an average revenue estimate of $5.06M. In the same quarter a year ago, actual revenue was $1.04MBased on 14 analysts’ estimates, the company’s revenue will be $58.51M in the next fiscal year. The high estimate is $111.58M and the low estimate is $25.11M.
